# Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

> **NCT07493668** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CHA University** · enrollment: 80 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Fostrox
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07493668
- **Lead sponsor:** CHA University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-27
- **Primary completion:** 2028-04-27
- **Final completion:** 2029-04-27
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493668, "Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07493668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*